The Care Program Approach (CPA) was implemented in 1991 to enhance community care for individuals with severe mental illness. The CPA comprises four primary components, including assessment, a care plan, a Care Coordinator (formerly known as a Key Worker), and regular review. There are two levels of CPA, namely standard and enhanced. Standard care plans are suitable for individuals who require minimal input from a single agency and pose minimal risk to themselves of others. Enhanced care plans are designed for individuals with complex needs who require collaboration among multiple agencies.

The History of Psychosurgery

Psychosurgery, the surgical treatment of mental illness, has a long and controversial history. The modern era of psychosurgery began in the late 19th century with the pioneering work of Swiss neurosurgeon Burckhardt, who removed areas of cortex from the frontal and parietal regions of six patients.

In 1910, Russian neurosurgeon Puseep ablated the frontoparietal tracts of three bipolar patients. However, it was Egas Moniz who refined psychosurgical techniques and was awarded the Nobel Prize for Medicine in 1949 for his work in the treatment of psychiatric disorders.

American neurosurgeon Freeman also developed similar procedures and advocated for psychosurgery as a first-line treatment for mental illness. Luver and Bucy described the effect of temporal lobectomy on aggression, further advancing the field of psychosurgery. Despite its controversial history, psychosurgery continues to be used today in select cases as a treatment option for severe mental illness.

The recovery model raises questions about how to define recovery from a mental health problem. Mental health services tend to define recovery based on measures such as symptom remission, hospitalization, independence, and involvement in work of school. However, people with mental health problems define recovery differently, placing importance on factors such as overcoming the effects of being a patient, establishing a fulfilling life and positive identity, and discovering how to live well with enduring symptoms.

Preventative Treatment Options for Psychosis

According to NICE guidelines, individual cognitive-behavioral therapy (CBT) is a recommended preventative treatment option for individuals at high risk of developing psychosis, with of without family intervention. However, antipsychotic medication is not recommended for preventing of reducing the risk of psychosis. Dialectic behavior therapy (DBT) is typically used for patients with borderline personality disorder, while omega 3 fatty acids have shown some potential in treating refractory schizophrenia. Psychodynamic psychotherapy is generally not recommended for possible early onset psychosis.

Neurostimulation is a treatment that uses electromagnetic energy targeted at the brain. There are several forms of neurostimulation, including TMS, deep brain stimulation, and ECT. TMS is a non-invasive, non-convulsive technique used to stimulate neural tissue. It involves the placement of an electromagnetic coil on the patient’s scalp to deliver a short, powerful magnetic field pulse through the scalp and induce electric current in the brain. TMS is used to treat depression when standard treatments have failed. Deep brain stimulation is a neurosurgical technique that involves placing an electrode within the brain to deliver a high-frequency current in a specific subcortical of deep cortical structure. It has been used to treat Parkinson’s, dysthymia, OCD, and Tourette syndrome. There is RCT evidence to demonstrate its effectiveness in OCD, but conflicting results in depression and Tourette’s. DBS is also being trailed in other conditions such as anorexia, bipolar, and additions.

This intervention is designed to prevent depression in a broad population, making it applicable to everyone and can be categorized as either a universal of primary prevention strategy.

Prevention measures can be classified into different levels, depending on the stage at which they are implemented. The first model, developed in the 1960s, includes primary, secondary, and tertiary prevention. Primary prevention aims to intervene before a disease of problem begins, and can be universal (targeted to the general public), selective (targeted to a high-risk population), of indicated (targeted to individuals with minimal but detectable signs of a disorder). Secondary prevention aims to detect and treat disease that has not yet become symptomatic, while tertiary prevention involves the care of established disease.

A newer model, developed in 1992, focuses on prevention interventions used before the initial onset of a disorder. This model also includes three levels: universal prevention (targeted to the general population), selective prevention (targeted to a high-risk population), and indicated prevention (targeted to individuals with minimal but detectable signs of a disorder). Examples of prevention measures include cognitive interventions for adolescents with cognitive deficits to prevent the later phases of schizophrenia, screening procedures for early detection and treatment of disease, and the use of low-dose atypical antipsychotics and CBT for patients with prodromal symptoms of schizophrenia to delay of prevent disease onset.

The Rapid Assessment Interface and Discharge (RAID) psychiatric liaison service at Birmingham’s City Hospital was evaluated by the London School of Economics, which found that the benefit:cost ratio was over 4:1. The evaluation showed that the service resulted in savings of £3.55 million per year in general hospital bed use, at a cost of £0.8 million.

In essence, the most appropriate term to describe this intervention is tertiary prevention since universal, indicated, and selective prevention strategies target individuals before the onset of a full-blown illness.

Prevention measures can be classified into different levels, depending on the stage at which they are implemented. The first model, developed in the 1960s, includes primary, secondary, and tertiary prevention. Primary prevention aims to intervene before a disease of problem begins, and can be universal (targeted to the general public), selective (targeted to a high-risk population), of indicated (targeted to individuals with minimal but detectable signs of a disorder). Secondary prevention aims to detect and treat disease that has not yet become symptomatic, while tertiary prevention involves the care of established disease.

A newer model, developed in 1992, focuses on prevention interventions used before the initial onset of a disorder. This model also includes three levels: universal prevention (targeted to the general population), selective prevention (targeted to a high-risk population), and indicated prevention (targeted to individuals with minimal but detectable signs of a disorder). Examples of prevention measures include cognitive interventions for adolescents with cognitive deficits to prevent the later phases of schizophrenia, screening procedures for early detection and treatment of disease, and the use of low-dose atypical antipsychotics and CBT for patients with prodromal symptoms of schizophrenia to delay of prevent disease onset.

According to Greenhalgh (1997), when making decisions about clinical interventions, the standard notation for the relative weight carried by different types of primary studies is arranged in a hierarchy of evidence. Randomised control trials with non-definitive results are ranked third in this hierarchy, carrying stronger relative weight than cohort studies, case-control studies, cross-sectional surveys, and case reports. The top two positions are occupied by systematic reviews/meta-analyses and RCTs with definitive results, respectively.

ECT (Treatment) – Summary of Effectiveness and Recommendations

ECT (Electroconvulsive Therapy) is a treatment that induces a therapeutic seizure through the application of electrical current under general anesthesia and muscle relaxation. It is prescribed as a course and is usually administered twice weekly for 6 to 12 treatments. ECT is the most effective short-term treatment for major depression, with remission rates of around 60-80% when used as first-line treatment in a severe depressive episode. However, without maintenance treatment, the relapse rate is extremely high (over 80%) in the 6 months after successful ECT.

Cognitive effects are the main limitation to the wider use of ECT, particularly acute confusion shortly after the treatment, retrograde amnesia, and some losses in autobiographical memory longer term. The current state of evidence does not allow the general use of ECT in the management of schizophrenia. Bilateral ECT is more effective than unilateral ECT but may cause more cognitive impairment. With unilateral ECT, a higher stimulus dose is associated with greater efficacy but also increased cognitive impairment compared with a lower stimulus dose.

NICE (National Institute for Health and Care Excellence) recommends that ECT is used only to achieve rapid and short-term improvement of severe symptoms after an adequate trial of other treatment options has proven ineffective and/of when the condition is considered to be potentially life-threatening. ECT is recommended for individuals with severe depression (that is life-threatening and when a rapid response is required, of when other treatments have failed), moderate depression (consider it if their depression has not responded to multiple drug treatments and psychological treatment), catatonia, and a prolonged of severe manic episode.

The RCPsych (Royal College of Psychiatrists) position on ECT recommends it as a first-line treatment for individuals with high suicidal risk, severe psychomotor retardation and associated problems of compromised eating and drinking and/of physical deterioration, treatment-resistant depression that has responded to ECT in a previous episode of illness, pregnant individuals with severe depression, of severe mixed affective states, mania of catatonia and whose physical health of that of the fetus is at serious risk, and those who prefer this form of treatment. ECT is recommended as a second-line treatment for individuals with treatment-resistant depression, severe side-effects from medication, and persistent of life-threatening symptoms in severe of prolonged mania. ECT is indicated in some circumstances for individuals with bipolar depression, postnatal psychosis, treatment-resistant schizophrenia, treatment-resistant catatonia, and frequent relapses and recurrences of depression (maintenance).

Principles of Prevention for Depression

Depression can be prevented through various principles of prevention. According to an article on depression prevention, there are different levels of prevention that aim to reduce the incidence, prevalence, and associated disability of depression.

Primary prevention focuses on reducing the occurrence of depression in the general population. This can be achieved through public health campaigns, education, and awareness programs.

Secondary prevention targets subgroups of the population who are identified as at risk for depression. This can include individuals with a family history of depression, those who have experienced traumatic events, of those with chronic illnesses.

Tertiary prevention aims to reduce the disability associated with depression. This can involve providing support and treatment to individuals who have already developed depression, in order to prevent further complications and improve their quality of life.

Universal prevention targets the entire population, while selective prevention targets specific subgroups. Indicated prevention targets individuals who are at a prodromal stage of depression, meaning they are showing early signs of the illness.

By implementing these principles of prevention, it is possible to reduce the incidence, prevalence, and disability associated with depression.

If a patient’s plasma clozapine to norclozapine ratio decreases while on a consistent clozapine dose, it may indicate enzyme induction. Conversely, an increase in the ratio may suggest enzyme inhibition of saturation, recent non-trough sample, of poor compliance. The clozapine to norclozapine ratio is typically stable among patients with stable clozapine doses.

According to a study conducted by the University of Sheffield, implementing a minimum unit price of 45 pence for alcohol could potentially save 624 lives and prevent 237,000 hospital admissions in England every year. Additionally, the research suggests that the ban on selling alcohol below cost, which was implemented in May 2014, could prevent 14 deaths and 500 hospital admissions annually.

Guidance for Registered Medical Practitioners on the Notification of Deaths Regulations 2019

If there is reason to suspect that the deceased died from self-inflicted poisoning, the coroner should be informed. The Notification of Deaths Regulations 2019 provides national guidance for registered medical practitioners on reporting deaths. This guidance supersedes any local protocols. There are several causes of death that must be referred to the coroner, including death from poisoning, violence of trauma, self-harm, neglect, medical procedures, employment-related injury of disease, unnatural death, unknown cause of death, death in state detention, and unidentified individuals. This does not include patients recently detained under the Mental Health Act of subject to DOLS, unless one of the above reasons applies.

The advancements in technology and the widespread availability of smartphones and internet access can be utilized to improve patient care and equip clinicians with more tools for diagnosing and treating mental illnesses. One promising approach is avatar therapy, which has shown positive results in treating auditory hallucinations in patients who did not respond well to medication. Additionally, automated objective behavioral analysis has been used to monitor and predict mood and emotional responses. However, online cognitive behavioral therapy has not been found to be effective in treating auditory hallucinations. Personal Zen is a mobile and tablet app that gamifies techniques proven to be helpful in managing anxiety and stress. Finally, virtual reality exposure therapy has been used to treat post-traumatic stress disorder.

DBS, a type of neurosurgery, is typically conducted in an operating theatre and has been shown to be effective in treating OCD based on randomized controlled trial (RCT) data. However, there are currently no NICE Guidelines available for DBS.

Neurostimulation is a treatment that uses electromagnetic energy targeted at the brain. There are several forms of neurostimulation, including TMS, deep brain stimulation, and ECT. TMS is a non-invasive, non-convulsive technique used to stimulate neural tissue. It involves the placement of an electromagnetic coil on the patient’s scalp to deliver a short, powerful magnetic field pulse through the scalp and induce electric current in the brain. TMS is used to treat depression when standard treatments have failed. Deep brain stimulation is a neurosurgical technique that involves placing an electrode within the brain to deliver a high-frequency current in a specific subcortical of deep cortical structure. It has been used to treat Parkinson’s, dysthymia, OCD, and Tourette syndrome. There is RCT evidence to demonstrate its effectiveness in OCD, but conflicting results in depression and Tourette’s. DBS is also being trailed in other conditions such as anorexia, bipolar, and additions.

DBS can lead to various complications, such as intracranial bleeding (which occurs in around 2.0-2.5% of implants), dislocation, lead fracture, and infection. Additionally, stimulation-induced adverse side effects may include paraesthesia, tonic muscle contractions, dyskinesia, and gait ataxia. While less common, some individuals may experience side effects such as aggression, mirthful laughter, depression, penile erection, of mania.

Non-Pharmacological Interventions for Treatment-Resistant Depression

One non-pharmacological intervention for treatment-resistant depression is repetitive transcranial magnetic stimulation (rTMS). This outpatient procedure involves using an electromagnetic coil to induce electric currents in the cerebral cortex without the need for anesthesia. It is typically used for patients who have not responded to antidepressant medication of for whom antidepressants are not suitable. Treatment can be delivered unilaterally or bilaterally and lasts for 2 to 6 weeks.

Electroconvulsive therapy (ECT) is another option for treatment-resistant depression, but it is associated with adverse effects such as autobiographical retrograde memory loss. It is not recommended for patients who have recently had a heart attack and are keen to avoid side effects.

Psychosurgery is rarely used and only as a last resort for severely debilitating mental illness. It is associated with seizures and permanent cognitive impairment.

Deep brain stimulation (DBS) is a controversial option for treatment-resistant depression. It involves targeting specific areas of the brain, such as the subcallosal cingulate and medial forebrain bundle. However, it is not currently recommended by NICE and is more commonly used for Parkinson’s disorder.

Lithium may also be an option, but the question specifically asks for non-pharmacological interventions.

ECT (Treatment) – Summary of Effectiveness and Recommendations

ECT (Electroconvulsive Therapy) is a treatment that induces a therapeutic seizure through the application of electrical current under general anesthesia and muscle relaxation. It is prescribed as a course and is usually administered twice weekly for 6 to 12 treatments. ECT is the most effective short-term treatment for major depression, with remission rates of around 60-80% when used as first-line treatment in a severe depressive episode. However, without maintenance treatment, the relapse rate is extremely high (over 80%) in the 6 months after successful ECT.

Cognitive effects are the main limitation to the wider use of ECT, particularly acute confusion shortly after the treatment, retrograde amnesia, and some losses in autobiographical memory longer term. The current state of evidence does not allow the general use of ECT in the management of schizophrenia. Bilateral ECT is more effective than unilateral ECT but may cause more cognitive impairment. With unilateral ECT, a higher stimulus dose is associated with greater efficacy but also increased cognitive impairment compared with a lower stimulus dose.

NICE (National Institute for Health and Care Excellence) recommends that ECT is used only to achieve rapid and short-term improvement of severe symptoms after an adequate trial of other treatment options has proven ineffective and/of when the condition is considered to be potentially life-threatening. ECT is recommended for individuals with severe depression (that is life-threatening and when a rapid response is required, of when other treatments have failed), moderate depression (consider it if their depression has not responded to multiple drug treatments and psychological treatment), catatonia, and a prolonged of severe manic episode.

The RCPsych (Royal College of Psychiatrists) position on ECT recommends it as a first-line treatment for individuals with high suicidal risk, severe psychomotor retardation and associated problems of compromised eating and drinking and/of physical deterioration, treatment-resistant depression that has responded to ECT in a previous episode of illness, pregnant individuals with severe depression, of severe mixed affective states, mania of catatonia and whose physical health of that of the fetus is at serious risk, and those who prefer this form of treatment. ECT is recommended as a second-line treatment for individuals with treatment-resistant depression, severe side-effects from medication, and persistent of life-threatening symptoms in severe of prolonged mania. ECT is indicated in some circumstances for individuals with bipolar depression, postnatal psychosis, treatment-resistant schizophrenia, treatment-resistant catatonia, and frequent relapses and recurrences of depression (maintenance).

The Care Program Approach (CPA) was implemented in 1991 to enhance community care for individuals with severe mental illness. The CPA comprises four primary components, including assessment, a care plan, a Care Coordinator (formerly known as a Key Worker), and regular review. There are two levels of CPA, namely standard and enhanced. Standard care plans are suitable for individuals who require minimal input from a single agency and pose minimal risk to themselves of others. Enhanced care plans are designed for individuals with complex needs who require collaboration among multiple agencies.

A randomized control trial conducted by Prakash demonstrated that the memory enhancing drug, donepezil hydrochloride, can decrease the time required for recovery after undergoing ECT. This finding suggests that donepezil may have therapeutic and prophylactic benefits for patients undergoing ECT. The study was published in the Journal of ECT in 2006.

ECT and Seizure Duration: Effect of Psychotropics

On the whole, most drugs do not interfere with ECT. However, it is important to note the effect of psychotropics on seizure duration. The table below summarizes the effect of important psychotropics and their advice:

Psychotropic class: Benzodiazepine
Effect on seizure duration: Reduced
Advice: Avoid where possible

Psychotropic class: SSRIs
Effect on seizure duration: Minimal effect

Psychotropic class: Venlafaxine
Effect on seizure duration: Minimal effect

Psychotropic class: TCAs
Effect on seizure duration: Possibly increased
Advice: TCAs are associated with arrhythmia following ECT in the elderly and those with cardiac disease, so they should be avoided in ECT in these groups.

Psychotropic class: MAOIs
Effect on seizure duration: Minimal effect

Psychotropic class: Lithium
Effect on seizure duration: Possibly increased
Advice: Generally used in ECT without significant problems.

Psychotropic class: Antipsychotics
Effect on seizure duration: Some potential increase in clozapine and phenothiazines, other antipsychotics considered ok
Advice: Limited data.

Psychotropic class: Anticonvulsants
Effect on seizure duration: Reduced
Advice: If used as a mood stabilizer, continue but be prepared to use higher energy stimulus.

(Source: Maudsley Guidelines 10th Edition, p.187)

History of ECT

ECT, of electroconvulsive therapy, was first developed in Italy in 1938. Prior to this, convulsive therapy had been used in various forms throughout the 1930s. However, it was not until Ugo Cerletti’s invention of ECT that a more controlled and effective method of inducing convulsions was developed. Cerletti’s first successful use of ECT involved producing a convulsion in a man in 1938. Since then, ECT has been used as a treatment for various mental health conditions, although its use has been controversial and subject to debate.

The ECTAS Guidelines 2019 recommend a frequency of two times per week.

ECT (Treatment) – Summary of Effectiveness and Recommendations

ECT (Electroconvulsive Therapy) is a treatment that induces a therapeutic seizure through the application of electrical current under general anesthesia and muscle relaxation. It is prescribed as a course and is usually administered twice weekly for 6 to 12 treatments. ECT is the most effective short-term treatment for major depression, with remission rates of around 60-80% when used as first-line treatment in a severe depressive episode. However, without maintenance treatment, the relapse rate is extremely high (over 80%) in the 6 months after successful ECT.

Cognitive effects are the main limitation to the wider use of ECT, particularly acute confusion shortly after the treatment, retrograde amnesia, and some losses in autobiographical memory longer term. The current state of evidence does not allow the general use of ECT in the management of schizophrenia. Bilateral ECT is more effective than unilateral ECT but may cause more cognitive impairment. With unilateral ECT, a higher stimulus dose is associated with greater efficacy but also increased cognitive impairment compared with a lower stimulus dose.

NICE (National Institute for Health and Care Excellence) recommends that ECT is used only to achieve rapid and short-term improvement of severe symptoms after an adequate trial of other treatment options has proven ineffective and/of when the condition is considered to be potentially life-threatening. ECT is recommended for individuals with severe depression (that is life-threatening and when a rapid response is required, of when other treatments have failed), moderate depression (consider it if their depression has not responded to multiple drug treatments and psychological treatment), catatonia, and a prolonged of severe manic episode.

The RCPsych (Royal College of Psychiatrists) position on ECT recommends it as a first-line treatment for individuals with high suicidal risk, severe psychomotor retardation and associated problems of compromised eating and drinking and/of physical deterioration, treatment-resistant depression that has responded to ECT in a previous episode of illness, pregnant individuals with severe depression, of severe mixed affective states, mania of catatonia and whose physical health of that of the fetus is at serious risk, and those who prefer this form of treatment. ECT is recommended as a second-line treatment for individuals with treatment-resistant depression, severe side-effects from medication, and persistent of life-threatening symptoms in severe of prolonged mania. ECT is indicated in some circumstances for individuals with bipolar depression, postnatal psychosis, treatment-resistant schizophrenia, treatment-resistant catatonia, and frequent relapses and recurrences of depression (maintenance).

While ECT may be considered for moderate depression in certain cases, it should not be administered if it goes against a legally binding advance decision of directive.

ECT (Treatment) – Summary of Effectiveness and Recommendations

ECT (Electroconvulsive Therapy) is a treatment that induces a therapeutic seizure through the application of electrical current under general anesthesia and muscle relaxation. It is prescribed as a course and is usually administered twice weekly for 6 to 12 treatments. ECT is the most effective short-term treatment for major depression, with remission rates of around 60-80% when used as first-line treatment in a severe depressive episode. However, without maintenance treatment, the relapse rate is extremely high (over 80%) in the 6 months after successful ECT.

Cognitive effects are the main limitation to the wider use of ECT, particularly acute confusion shortly after the treatment, retrograde amnesia, and some losses in autobiographical memory longer term. The current state of evidence does not allow the general use of ECT in the management of schizophrenia. Bilateral ECT is more effective than unilateral ECT but may cause more cognitive impairment. With unilateral ECT, a higher stimulus dose is associated with greater efficacy but also increased cognitive impairment compared with a lower stimulus dose.

NICE (National Institute for Health and Care Excellence) recommends that ECT is used only to achieve rapid and short-term improvement of severe symptoms after an adequate trial of other treatment options has proven ineffective and/of when the condition is considered to be potentially life-threatening. ECT is recommended for individuals with severe depression (that is life-threatening and when a rapid response is required, of when other treatments have failed), moderate depression (consider it if their depression has not responded to multiple drug treatments and psychological treatment), catatonia, and a prolonged of severe manic episode.

The RCPsych (Royal College of Psychiatrists) position on ECT recommends it as a first-line treatment for individuals with high suicidal risk, severe psychomotor retardation and associated problems of compromised eating and drinking and/of physical deterioration, treatment-resistant depression that has responded to ECT in a previous episode of illness, pregnant individuals with severe depression, of severe mixed affective states, mania of catatonia and whose physical health of that of the fetus is at serious risk, and those who prefer this form of treatment. ECT is recommended as a second-line treatment for individuals with treatment-resistant depression, severe side-effects from medication, and persistent of life-threatening symptoms in severe of prolonged mania. ECT is indicated in some circumstances for individuals with bipolar depression, postnatal psychosis, treatment-resistant schizophrenia, treatment-resistant catatonia, and frequent relapses and recurrences of depression (maintenance).

Research has consistently shown that out-patient services, whether they are general of specialized eating disorder clinics, are more likely to be cost-effective than in-patient care. The majority of patients with eating disorders can be effectively managed in out-patient clinics, with only a small percentage requiring in-patient care. When comparing outpatient treatment models, including general child and adolescent mental health services, with in-patient treatment, there were significant improvements in all groups at different points during follow-up, with no significant differences between the two types of treatment. The availability of out-patient care is associated with a lower rate of admission to inpatient units. Clinically and economically, lengthy in-patient stays are not recommended, as they are associated with worse outcomes, particularly when they disrupt the patient’s life, such as their work, studies, of time away from family.

Prevention measures can be classified into different levels, depending on the stage at which they are implemented. The first model, developed in the 1960s, includes primary, secondary, and tertiary prevention. Primary prevention aims to intervene before a disease of problem begins, and can be universal (targeted to the general public), selective (targeted to a high-risk population), of indicated (targeted to individuals with minimal but detectable signs of a disorder). Secondary prevention aims to detect and treat disease that has not yet become symptomatic, while tertiary prevention involves the care of established disease.

A newer model, developed in 1992, focuses on prevention interventions used before the initial onset of a disorder. This model also includes three levels: universal prevention (targeted to the general population), selective prevention (targeted to a high-risk population), and indicated prevention (targeted to individuals with minimal but detectable signs of a disorder). Examples of prevention measures include cognitive interventions for adolescents with cognitive deficits to prevent the later phases of schizophrenia, screening procedures for early detection and treatment of disease, and the use of low-dose atypical antipsychotics and CBT for patients with prodromal symptoms of schizophrenia to delay of prevent disease onset.

ECT and Seizure Duration: Effect of Psychotropics

On the whole, most drugs do not interfere with ECT. However, it is important to note the effect of psychotropics on seizure duration. The table below summarizes the effect of important psychotropics and their advice:

Psychotropic class: Benzodiazepine
Effect on seizure duration: Reduced
Advice: Avoid where possible

Psychotropic class: SSRIs
Effect on seizure duration: Minimal effect

Psychotropic class: Venlafaxine
Effect on seizure duration: Minimal effect

Psychotropic class: TCAs
Effect on seizure duration: Possibly increased
Advice: TCAs are associated with arrhythmia following ECT in the elderly and those with cardiac disease, so they should be avoided in ECT in these groups.

Psychotropic class: MAOIs
Effect on seizure duration: Minimal effect

Psychotropic class: Lithium
Effect on seizure duration: Possibly increased
Advice: Generally used in ECT without significant problems.

Psychotropic class: Antipsychotics
Effect on seizure duration: Some potential increase in clozapine and phenothiazines, other antipsychotics considered ok
Advice: Limited data.

Psychotropic class: Anticonvulsants
Effect on seizure duration: Reduced
Advice: If used as a mood stabilizer, continue but be prepared to use higher energy stimulus.

(Source: Maudsley Guidelines 10th Edition, p.187)

– ABV indicates the number of units of alcohol per litre of a liquid.
– The total number of alcoholic units in any given amount of liquid may be calculated by multiplying the volume of liquid (ml) by the ABV and dividing by 1000.
– A 1L bottle of 20% ABV port contains 20 units of alcohol.
– 6 large (250 ml) glasses of 12% ABV wine contain 18 units of alcohol.
– 12 330ml bottles of 5% ABV lager contain 20 units of alcohol.
– 12 500 ml bottles of 4% ABV ‘alcopop’ contain 24 units of alcohol.
– 20 standard (25 ml) measures of 40% ABV whiskey contain 20 units of alcohol.

In ECT, a seizure lasting more than 120 seconds is considered prolonged and can be stopped with intravenous diazepam. While there is no clear link between treatment success and seizure duration, it is advised to adjust the electricity dose to achieve a seizure lasting between 20 and 50 seconds. Short seizures may not be effective, while longer seizures may lead to cognitive issues.